According to the latest financial results, Torrent Pharmaceuticals Ltd. reported mixed financial results for the fourth quarter of FY26. The pharmaceutical giant's consolidated net profit declined 22% year-on-year to ₹389 crore compared to ₹498 crore in the corresponding period last year. The fall in bottom line was attributed to a 37% year-on-year rise in expenses to ₹3,585 crore in the March quarter, marking the company's first quarter after the integration of JB Pharmaceuticals. Despite the profit decline, the company demonstrated strong revenue growth with consolidated sales rising 42% to ₹4,197 crore against ₹2,959 crore in the same period last year. The company's operating profit margin (OPM) contracted to 32.3% from 33.14% in the year-ago quarter, reflecting the impact of higher operational costs.
On the operational front, Torrent Pharma showed robust performance with consolidated earnings before interest, taxes, depreciation and amortisation (EBITDA) standing at ₹1,356 crore with an EBITDA margin of 32.3%. However, this EBITDA figure excludes exceptional items such as regulatory and statutory fees and severance pay, along with other related costs associated with JB Pharma's acquisition worth ₹66 crore. The decline in bottom line was partly impacted by these exceptional items, which rose to ₹66 crore compared to an exceptional loss of ₹24 crore in the previous year's quarter. The company's profit before tax (PBT) declined 14% to ₹595 crore from ₹689 crore in the previous year's quarter. As per the latest reports, EBITDA jumped 40.7% to ₹1,356 crore from ₹964 crore in the year-ago quarter, demonstrating strong operational efficiency despite margin pressures.
The company's domestic performance was particularly strong, with India business revenue standing at ₹2,215 crore, up 43% in the quarter, led by outperformance in focus therapies and generic semaglutide performance. As per the company's regulatory filing, Torrent Pharma reported that generic semaglutide launch was off to a strong start with a combined 38% market share for oral and injectable doses. This domestic growth was complemented by strong international performance, with US business revenue at ₹396 crore, up 31% year-on-year, attributed to new product launches. Revenue from the Brazil market grew 30% Y-o-Y to ₹455 crore, compared with ₹351 crore in Q4 FY25, supported by strong performance of key brands and recent launches. The company is also betting on India's fast-growing obesity-drug market, having launched semaglutide in pen-filled injectable form on 21 March, with 5% market share as of April.
The drugmaker announced its results after market hours, with shares of Torrent Pharmaceuticals rising marginally by 0.62% to close at ₹4,497 apiece on the NSE on Friday, compared to a 0.27% advance in the Nifty index. The company has declared a final dividend of ₹9 per equity share with a record date set as May 29, 2026. Additionally, the drugmaker has announced plans of raising up to ₹5,000 crore via qualified institutional placements and other modes to support future growth initiatives. For the full financial year FY26, Torrent Pharma demonstrated strong annual performance with consolidated net profit rising 11.88% to ₹2,138 crore compared to ₹1,911 crore in the previous year. The company's annual sales grew 21.53% to ₹13,980 crore against ₹11,516 crore in FY5, with the operating profit margin for the full year standing at 32.88% compared to 33.15% in the previous year.
